94% of patients suing Merck over rofecoxib agree to terms of company's offer

Charatan, Fred
March 2008
BMJ: British Medical Journal (International Edition);3/15/2008, Vol. 336 Issue 7644, p580
Academic Journal
The article reports on a decision from 94% of patients suing Merck to accept a settlement agreement which the company offered to them. The litigants sued Merck as a result of developing side effects from the company's drug Vioxx. Merck announced the $4.98 billion settlement in November of 2007, and indicated that individual awards contained within it would range on average from $150,000 to $200,000. To receive the awards litigants must provide evidence of a Vioxx related heart attack or stroke, proof that they received at least thirty Vioxx pills, and evidence that they took at least one pill prior to their medical event.


Related Articles

  • THE UNEXPECTED REGULATOR: REGULATION THROUGH SETTLEMENT AFTER VIOXX AND BEXTRA. Allen, Warren // Brooklyn Journal of Corporate, Financial & Commercial Law;Spring2012, Vol. 6 Issue 2, p565 

    The article illustrates the need for some limitation on state regulation by litigation in the U.S., as demonstrated by the settlements involving the drugs Vioxx of Merck and Bextra of Pfizer, and proposes an alternative that integrates the state Attorneys General (AGs) into the federal...

  • Florida Sues Merck Over Vioxx Costs. News, Bloomberg // njbiz;10/6/2008, Vol. 21 Issue 41, p12 

    The article reports on a lawsuit filed by the state of Florida against Merck and Co. over alleged false marketing of the painkiller Vioxx. The lawsuit claims that Merck failed to disclose the risks of the drug before halting sales in 2004. States including Alaska, Louisiana and Michigan also...

  • Merck to pay $US58m in Vioxx settlement.  // PharmacoEconomics & Outcomes News;6/14/2008, Issue 555, p9 

    The article reports on the U.S. $58 million to be paid by Merck & Co. in a U.S. civil settlement reached over allegations that 1999 advertising for rofecoxib or Vioxx was misleading. According to attorney general of Pennsylvania Tom Corbett, Merck had launched an aggressive and deceptive...

  • Merck to Pay Another $58M for Vioxx Claims.  // njbiz;5/26/2008, Vol. 21 Issue 22, p2 

    The article reports that pharmaceutical firm Merck & Co. has agreed to settle claims that advertisements for the withdrawn painkiller Vioxx hid the increased risks of the drugs. Merck will pay $58 million to 29 states in the U.S., including New Jersey. The settlement agreement would also prevent...

  • Is Merck Winning or Losing in the Vioxx Trials? Simons, John // Fortune;5/15/2006, Vol. 153 Issue 9, p28 

    This article discusses the lawsuit over Merck & Co. Inc.'s anti-inflammatory drug Vioxx, which consumers are claiming causes cardiovascular damage. Over 11,500 lawsuit cases have been filed against Merck & Co. Inc., including a $32 million judgment against them in Texas. The drug company plans...

  • Merck sits tight on Vioxx. Mirasol, Feliza // Chemical Market Reporter;8/28/2006, Vol. 270 Issue 7, p18 

    The article reports on the efforts of Merck & Co. Inc. to defend each court cases filed over the negative health risks of its Vioxx painkiller in the U.S. Merck has dealt with wins and losses in various courts since September 2005. Despite the company's losses over Vioxx, it has been observed...

  • U.S. court dismisses some Vioxx cases for trial abroad.  // International Law Update;Sep2006, Vol. 12, p179 

    The article reports on the dismissal of some cases involving Merck & Co.'s painkiller Vioxx by the U.S. court for trial abroad. Plaintiffs from 11 foreign nations have sued Merck claiming that Vioxx had caused heart attacks and strokes and that Merck had failed to warn them of those risks. The...

  • Got Capped. Maleske, Melissa // InsideCounsel;Oct2008, Vol. 18 Issue 203, p13 

    The article discusses a court case wherein New Orleans federal district judge Eldon Fallon capped plaintiff's attorney's fees at 32 percent in the $4.85 billion Vioxx settlement. The judge ruled that the life-threatening injuries suffered by many of the plaintiffs made it difficult for them to...

  • Vioxx's Runaway Jury. Henderson, David R. // Reason;Dec2005, Vol. 37 Issue 7, p71 

    Considers the consequences of the jury's verdict in the personal injury lawsuit filed against Merck & Co. Inc. in Angleton, Texas. Ruling by the Texas jury on the case; Effects of the court's decision on every U.S. citizens; Implications of the court's decision on drug development in the country.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics